


Salmeterol Xinafoate

Chemical Properties

CAS No. :	94749-08-3
Formula:	C ₃₆ H ₄₅ N ₇ O ₇
Molecular Weight:	603.75
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Salmeterol Xinafoate (GR 33343X xinafoate) is a long-acting β_2 -adrenergic receptor agonist with anti-inflammatory effects, used in the treatment of asthma symptoms and chronic obstructive pulmonary disease (COPD) symptoms.
Targets(IC50)	HIV Protease, Adrenergic Receptor
In vitro	Salmeterol significantly inhibits production of pro-inflammatory mediators by RAW264.7 and THP-1 cells. Salmeterol downregulates PgLPS-mediated phosphorylation of the ERK1/2 and JNK but not p38 MAP kinases (MAP-K). Salmeterol also attenuates the activation of NF- κ B via inhibition of nuclear translocation of p65-NF κ B, the transcriptional activity of NF- κ B and I κ B α phosphorylation. Salmeterol shows very high selectivity for the WT β_2 AR (β_1 Ki / β_2 Ki ratio of approximately 1500) with Ki of 1.5 \pm 0.4 nM. Salmeterol prevents phosphorylation levels of IRS-1 Ser307 induced by tumor necrosis factor- α . Salmeterol alone prevents cell death in retinal Müller cells (p<0.05 versus 25 mM glucose). Salmeterol in combination with IRS-1 shRNA shows a significant increase in cell death compared to salmeterol alone. Moreover, salmeterol alone treatment significantly reduces cytochrome C levels, with the effect lessened when salmeterol is combined with IRS-1 shRNA. Salmeterol (100 μ M) causes apoptosis of DCs, and can not affect the differentiation and maturation of DCs at 10 μ M. Salmeterol (10 μ M) decreases the mRNA and protein levels of pro-inflammatory cytokines in LPS-activated DCs and inhibits MAPK and NF- κ B activation
In vivo	The OVA/LPS groups with salmeterol result in a significant decrease in the enhanced AHR in allergic mice in a dose-dependent manner. Salmeterol contends with asthma via regulating the inflammation of the airway of the mice.
Kinase Assay	The cells are rinsed twice with ice-cold phosphate-buffered saline and mechanically detached in ice-cold buffer containing 10 mM Tris·HCl, pH 7.4, 5 mM EDTA, 10 μ g/mL benzamidine, 10 μ g/mL soybean trypsin inhibitor (type II-S), and 5 μ g/mL leupeptin (lysis buffer). The lysate is centrifuged at 45,000 \times g for 10 min at 4°C. The pellet is rehomogenized in lysis buffer, with a Potter-type homogenizer, and stored at -80°C until use. The competition binding assays are performed in buffer containing 75 mM Tris·HCl, pH 7.4, 12.5 mM MgCl ₂ , and 2 mM EDTA, using 1-5 μ g of membrane protein, 50 pM 125I-CYP, and 0-100 μ M unlabeled ligand in the presence of 100 μ M GTP, for 60 min at 37°C. The binding reaction is terminated by dilution and rapid filtration through Whatman GF/C filters; the filters are washed three times with solution containing 25 mM Tris·HCl, pH 7.4, and 1 mM MgCl ₂ . Nonspecific binding is determined in the presence of 5 μ M (\pm)-

Kinase Assay	propranolol. The radioactivity on the filters is counted with a γ -counte
Animal Research	Salmeterol is formulated in PBS. All mice are sensitized on days 0 and 14 by intraperitoneal injection of either PBS or 0.08 mg OVA and 0.1 mL aluminum hydroxide in 0.1 mL of PBS (pH 7.4). After sensitization, animals are exposed to aerosolized PBS-only (negative control), 1% OVS/PBS (acute exposure), 1% OVA/0.01% LPS/PBS (extra LPS exposure) or 1% OVA/0.01% LPS/salmeterol/PBS (sal treatment) for 40 min, once per day for 3 consecutive days (days 24-26). On day 27, the mice are killed and lungs are divided into two groups for analysis: the left lung lobes are lavaged three times with 1 mL of PBS with 1% fetal calf serum and 5 U/mL heparin, and the right halves are fixed by 4% paraformaldehyde for histological analysis.

Solubility Information

Solubility	Ethanol: 12.1 mg/mL (20.04 mM), Sonication is recommended. DMSO: 142.8 mg/mL (236.52 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.31 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6563 mL	8.2816 mL	16.5631 mL
5 mM	0.3313 mL	1.6563 mL	3.3126 mL
10 mM	0.1656 mL	0.8282 mL	1.6563 mL
50 mM	0.0331 mL	0.1656 mL	0.3313 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Isogaya M, et al. Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. *Mol Pharmacol*. 1998 Oct;54(4):616-22.

Zhao J, Xu L, Bai Y, et al. The efficacy and mechanism of salmeterol against influenza A virus in vitro and in vivo. *International Immunopharmacology*. 2023, 119: 110226.

Walker, R., Anderson, N., BAhouth, S., & Steinle, J. (2012). Silencing of insulin receptor substrate-1 increases cell death in retinal Müller cells. *Mol Vis*, 18(27), 271-9.

Hu Z, et al. Salmeterol attenuates the inflammatory response in asthma and decreases the pro-inflammatory cytokine secretion of dendritic cells. *Cell Mol Immunol*. 2012 May;9(3):267-75.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481